Drug intelligence / Profile preview

ASF-IgY

Development stage: Preclinical
Lead developer: IGY Immune Technologies & Life Sciences
Modality: Antibody-Based Therapeutics

Overview

ASF-IgY is a polyclonal immunoglobulin Y (IgY) antibody candidate developed by IGY Immune Technologies & Life Sciences for the management of African Swine Fever (ASF) in animal health. The product is derived from the egg yolks of hens immunized with African Swine Fever Virus (ASFV) particles and viral proteins. The mechanism of action involves the binding of these polyclonal antibodies to ASFV particles, thereby neutralizing the virus and preventing its entry into host cells. This approach is intended to provide passive immunity to pigs, offering a potential intervention for a disease that currently lacks effective vaccines or treatments.

Other names: anti-African swine fever immunoglobulin Y

Targets

ASFV (African swine fever virus)

Beyond the preview

Go deeper on ASF-IgY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASF-IgY.

Explore the full profile